<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49071">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467400</url>
  </required_header>
  <id_info>
    <org_study_id>14-004305</org_study_id>
    <nct_id>NCT02467400</nct_id>
  </id_info>
  <brief_title>Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism</brief_title>
  <official_title>Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to answer the question as to whether the sympathetic nervous system
      is an important determinant of bone metabolism in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In postmenopausal women, who have increased sympathetic outflow, to test the hypothesis that
      treatment with low doses of a non-selective β-blocker (propranolol) will increase serum
      markers of bone formation and reduce markers of bone resorption (Aim 1a); and using
      increasingly β1-AR selective blockers (atenolol and nebivolol), to better define the
      β-adrenergic receptor selectivity (β1 versus β2) in the regulation of bone turnover by
      sympathetic outflow in humans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of serum bone formation to bone resorption marker</measure>
    <time_frame>20 weeks</time_frame>
    <description>Serum bone formation marker (PINP)/serum bone resorption marker (CTX)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Osteoporosis, Age-Related</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atenolol 50 mg 1/day for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebivolol 5 mg/day for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol 20 mg bid for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol 40 mg bid for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>beta blocker</description>
    <arm_group_label>Atenolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>beta blocker</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>beta blocker</description>
    <arm_group_label>Propranolol 40 mg</arm_group_label>
    <arm_group_label>Propranolol 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  at least 5 yrs since their last menses

               -  Follicle Stimulating Hormone (FSH) &gt; 20 IU/L

          -  Exclusion Criteria:

               -  Abnormality in any of the screening laboratory studies

               -  Presence of significant liver or renal disease

               -  Malignancy (including myeloma)

               -  Malabsorption

               -  Diabetes

               -  Hypoparathyroidism

               -  Hyperparathyroidism

               -  Acromegaly

               -  Cushing's syndrome

               -  Hypopituitarism

               -  Severe chronic obstructive pulmonary disease

               -  Undergoing treatment with any medications that affect bone turnover, including
                  the following:

          -  adrenocorticosteroids (&gt; 3 months at any time or &gt; 10 days within the previous yr)

          -  anticonvulsant therapy (within the previous year)

          -  pharmacological doses of thyroid hormone (causing decline of thyroid stimulating
             hormone below normal)

          -  calcium supplementation of &gt; 1200 mg/d (within the preceding 3 months)

          -  bisphosphonates (within the past 3 yrs)

          -  denosumab

          -  estrogen (E) therapy within the past year

          -  treatment with a selective E receptor modulator within the past year

          -  teriparatide within the past yr

          -  anti-hypertensive therapy

               -  Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm

               -  Recent (within the past 6 months) fracture

               -  Serum 25-hydroxyvitamin D levels of &lt; 20 ng/ml

               -  Resting blood pressure &gt;140/90 mm Hg or those with hypotension (systolic blood
                  pressure &lt;110 mm Hg), heart rate &lt; 60 bpm

               -  History of asthma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sundeep Khosla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammie Volkman, RN</last_name>
    <phone>507-538-6023</phone>
    <email>volkman.tammie@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 14, 2016</lastchanged_date>
  <firstreceived_date>June 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sundeep Khosla, M.D.</investigator_full_name>
    <investigator_title>Professor of Medicine and Physiology, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>bone formation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
